Johnson & Johnson (NYSE:JNJ) Shares Sold by Fishman Jay A Ltd. MI

Fishman Jay A Ltd. MI reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,955 shares of the company’s stock after selling 4,937 shares during the quarter. Johnson & Johnson comprises 1.5% of Fishman Jay A Ltd. MI’s investment portfolio, making the stock its 17th biggest holding. Fishman Jay A Ltd. MI’s holdings in Johnson & Johnson were worth $13,473,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. DORCHESTER WEALTH MANAGEMENT Co lifted its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after acquiring an additional 414 shares during the period. OneAscent Financial Services LLC raised its holdings in Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares during the last quarter. TrueMark Investments LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $1,458,000. RAM Investment Partners LLC grew its holdings in Johnson & Johnson by 4.5% in the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after purchasing an additional 73 shares during the last quarter. Finally, RFG Advisory LLC increased its position in shares of Johnson & Johnson by 12.6% in the third quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock valued at $2,921,000 after buying an additional 2,102 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $177.31.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.5 %

Shares of NYSE:JNJ opened at $152.31 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market cap of $367.03 billion, a price-to-earnings ratio of 11.03, a PEG ratio of 2.56 and a beta of 0.53. The stock’s 50-day moving average price is $157.79 and its two-hundred day moving average price is $156.18. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.28 by $0.01. The business had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period last year, the company earned $2.35 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.